Clinical Trial

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Study acronym: ENDURA -1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-28; most recent amendment 2025-10-06.
Status change: Not Yet Recruiting → Recruiting 2025-06-30
Trial Details
NCT Number NCT06959095
Lead Sponsor GlaxoSmithKline
Conditions Pulmonary Disease, Chronic Obstructive
Enrollment 981 participants
Start Date 2025-06-20
Primary Completion 2029-08-20 (estimated)
Study Completion 2029-08-20 (estimated)
Updated on ClinicalTrials.gov 2025-10-08